Ergoteles’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Ergoteles’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-121,650	Closed	-$9.15M	–	2219
2022 Q2	$9.15M	Buy	121,650 +84,276	+225%	+$3.75M	0.27%	97
2022 Q1	$1M	Buy	37,374 +22,206	+146%	+$746K	0.04%	423
2021 Q4	$724K	Buy	+15,168	New	+$678K	0.03%	511
2021 Q2	–	Sell	-42,465	Closed	-$4.02M	–	1757
2021 Q1	$4.02M	Buy	+42,465	New	+$5.05M	0.13%	192

Ergoteles's TPTX Position: Q3 2022 in Review

Ergoteles sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 121,650 shares — an estimated $9.15M sold.

Ergoteles first reported a position in TPTX in Q1 2021 and held it in 4 quarters. The position peaked at $9.15M in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Ergoteles reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Ergoteles sold 121,650 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $9.15M.
Ergoteles first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
Ergoteles's Turning Point Therapeutics, Inc. Common Stock position peaked at $9.15M in Q2 2022.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.